Skip to content
    Premier Partners logo

    Premier Partners

    Seoul, South KoreaFounded 2005
    premierpartners.co.krLinkedIn
    Biotech & Life SciencesHealthcareConsumerFintechData & Analytics

    Premier Partners is a Seoul-based private equity and venture capital firm founded in 2005 as Korea's first fund management firm under an LLC structure. Initially launched as a VC firm, it expanded into private equity in 2010 and now operates three divisions—Private Equity, Venture Capital, and Bio/Healthcare—investing across early-stage startups to mid-market companies.

    They made 1 investments in the last 12 months. Average disclosed round size is $2286.3M (across 20 rounds with reported amounts).

    Find people at Premier Partners on Goldilocks AI

    Portfolio

    33

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    DL

    Donghoon Lee

    Managing Partner

    JS

    Jay Song

    Managing Partner/Founder/CEO

    JC

    Joonyoun Cho

    Managing Partner

    SK

    Seong Kim

    Managing Partner/CEO

    YL

    Yongkee Lim

    Managing Partner/CRO

    DL

    Daniel Lee

    Managing Director

    HY

    Hayoung Yun

    Managing Director

    TW

    Tae Woong Kwon

    Managing Director

    BK

    Byeongchan Kim

    Partner

    DO

    David Oh

    Partner

    DJ

    Donghoon Jeon

    Partner

    EC

    Edward Cho

    Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    42 investments
    CompanyRoundAmountDate
    Elisigen logoElisigenSeries C—Sep 2026
    AutoGrab logoAutoGrabSeries B—Jan 2026
    Prazer Therapeutics logoPrazer TherapeuticsSeries B$20MJan 2025
    Neuracle logoNeuracleSeries C$26.1BJan 2025
    SSobaGenBridge—Jan 2025
    업업스테이지Series B$45MJan 2024
    Toss Bank logoToss BankUnknown$154MJan 2023
    Ideahub logoIdeahubUnknown$104.2MJan 2023
    Onconic Therapeutics logoOnconic TherapeuticsSeries B$19.9MDec 2022
    Superb AI logoSuperb AISeries B$16MSep 2022
    BoostImmune logoBoostImmuneSeries A—Jun 2022
    InDebted logoInDebtedSeries C—Jan 2022
    JeongYookGak logoJeongYookGakSeries D—Jan 2022
    Onconic Therapeutics logoOnconic TherapeuticsUnknown—Jan 2022
    SK ecoplant logoSK ecoplantUnknown—Jan 2022
    Aardvark logoAardvarkSeries B$29MJan 2021
    Ideahub logoIdeahubUnknown$13.9MJan 2021
    MEGA MGC COFFEE logoMEGA MGC COFFEEUnknown—Jan 2021
    Riiid logoRiiidSeries C$41.8MJul 2020
    HHealingpaperSeries B$18.5BApr 2020
    Skyroam logoSkyroamUnknown$20MOct 2019
    B2LINK logoB2LINKUnknown$15MJan 2019
    NNohla TherapeuticsSeries B$45MMay 2018
    Neumora Therapeutics logoNeumora TherapeuticsSeries B$112M—
    Neumora Therapeutics logoNeumora TherapeuticsSeries A$400M—
    Page 1 of 2

    Top Co-Investors

    Korea Development Bank9 shared
    Korea Investment Partners6 shared
    Stonebridge Partners5 shared
    IMM Investment4 shared
    AJU IB Investment4 shared
    InterVest3 shared
    Industrial Bank of Korea3 shared
    Mirae Asset3 shared
    SV Investment Corporation3 shared
    ARCH Venture Partners2 shared
    Amgen Ventures2 shared
    Vickers Venture Partners2 shared
    DSC Investment2 shared
    Atinum Investment2 shared
    Springcamp2 shared
    Legend Capital2 shared
    SBI Investment2 shared
    F-Prime Capital1 shared
    Exor Ventures1 shared
    Mubadala Ventures1 shared

    Last updated: 8 September 2026